CCP
VRTX icon

Clough Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Clough Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-140,000
Closed -$25.4M – 134
2021
Q3 		$25.4M Buy
140,000
+60,500
+76% +$11.8M 1.54% 22
2021
Q2 		$16M Sell
79,500
-283,000
-78% -$59.2M 0.87% 48
2021
Q1 		$77.9M Buy
362,500
+212,500
+142% +$46.7M 3.48% 2
2020
Q4 		$35.5M Buy
+150,000
New +$34.4M 2.52% 7

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clough Capital Partners's VRTX Position: Q3 2023 in Review

Clough Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 26,041 shares — an estimated $9.16M sold.

Clough Capital Partners first reported a position in VRTX in Q3 2015 and held it in 32 quarters. The position peaked at $23.5M in Q4 2021. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Clough Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Clough Capital Partners sold 26,041 Vertex Pharmaceuticals shares in Q3 2023, an estimated $9.16M.
  • Clough Capital Partners first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 32 quarters.
  • Clough Capital Partners's Vertex Pharmaceuticals position peaked at $23.5M in Q4 2021.
  • 1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Clough Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.